CRTO enters the week after one of its worst single sessions in years. A Q1 2026 earnings report on May 6 sent the stock down 18.2% in a single day. It now trades at $16.20, down almost 20% on the week and roughly 9% lower over the past month.
The sell-off was severe enough to force an immediate reset across the Street. Wells Fargo's Alec Brondolo moved fast — downgrading from Overweight to Equal-Weight and slashing his target from $34 to $18 on May 7, the day after results. That is the most aggressive move in the recent batch. Benchmark's Mark Zgutowicz held his Buy but cut the target from $30 to $25 the same day. Then, just this morning, Morgan Stanley's Brian Nowak lowered to $29 from $33 while keeping Equal-Weight. The direction is unanimous: every analyst action since the print has been a target cut. The mean target across the coverage group now stands at roughly $24.64 — still well above the $16.20 price, implying meaningful notional upside. But with the stock priced where it is and the Street still adjusting, the gap reflects confusion rather than conviction.
The borrow market shows bears moving cautiously rather than aggressively. Short interest is modest — 2.0% of the free float, essentially flat over the week after a brief spike on April 24 and a gradual drift lower since. Cost to borrow has roughly doubled week-on-week to 2.14%, the highest level in the 30-day window, but in absolute terms it remains cheap. Availability is still wide, with borrow supply plentiful relative to current demand. The lending market is tightening at the margin after the print, but not yet signalling a crowded short or any squeeze pressure. Days to cover stands at 6.5 days by the official FINRA figure — elevated enough to warrant attention if short interest were to build, but not alarming at current levels.
Options positioning has shifted more defensively since the earnings drop. The put/call ratio now runs at 0.34, well above its 20-day mean of 0.24. That puts it roughly 1.3 standard deviations above normal — elevated, but a long way from the 52-week high of 1.08 reached during a more extreme risk-off moment. The move is visible in the history: the PCR spent most of April below 0.12, then doubled after the May 6 print and has held near those levels since. Investors are buying more protection. They are not yet in panic mode.
The factor picture adds nuance. CRTO's EV/EBITDA of 1.58 is strikingly low, and the stock's valuation relative to earnings history ranks near the top of the universe — the EV/EBIT factor score sits at the 94th percentile. The price-to-book of 0.62 is similarly compressed. These are value signals, not growth signals. EPS momentum scores tell the growth side of the story more honestly: the 30-day EPS momentum rank is just 22nd percentile, and the 90-day version is 24th. The company beat Q1 consensus by 16 cents per share, but forward expectations have deteriorated. The ORTEX short score of 33.7 is unremarkable — mid-range, and drifting slightly lower over the past two weeks, consistent with the modest short interest unwind.
The one note of genuine interest on the ownership side: the Chairman of the Board, Rik van der Kooi, bought 5,000 shares at $17.81 on March 13 — before the earnings collapse. That purchase is now underwater. It is a small transaction, and significance scores are low, but board-level buying at prices above the current market is a data point worth noting. The CFO and Chief Legal Officer have made smaller routine sells in February and March, consistent with scheduled liquidations rather than a directional view.
Peer context is mixed. DV — a close correlated name — fell 12.7% on the week, suggesting sector-wide pressure rather than a CRTO-specific story alone. MGNI was a notable exception, gaining 1.6% over the same period, and PUBM dropped around 6%. The ad-tech universe broadly absorbed collateral damage from the CRTO miss.
The next scheduled earnings event is not yet dated. What to watch: whether the Wells Fargo downgrade triggers further re-ratings from the remaining Buy-side holders, and whether short interest — still subdued — starts to rebuild as the revised analyst consensus settles in.
See the live data behind this article on ORTEX.
Open CRTO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
